A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

This study tests a drug called sacituzumab govitecan for people with advanced thymoma or thymic carcinoma (rare cancers of the thymus gland, a small organ in the chest) that has progressed despite prior treatment. The drug delivers chemotherapy directly to cancer cells using a targeted antibody. **You may be eligible if...** - You are 18 or older - You have confirmed advanced thymoma or thymic carcinoma - Your cancer has progressed after at least one prior treatment - You can be measured on scans (measurable disease) - You are in reasonably good physical condition - You have adequate blood counts and organ function **You may NOT be eligible if...** - You have not yet tried any systemic treatment - Your organ function is significantly impaired - You have active brain metastases - You are pregnant or breastfeeding - You have a serious active infection or autoimmune disease Talk to your doctor to see if this trial is right for you.